

MEDICAL POLICY



SUBJECT: BIOCHEMICAL MARKERS OF BONE TURNOVER	EFFECTIVE DATE: 02/20/03 REVISED DATE: 12/18/03, 12/16/04, 10/20/05, 08/17/06, 08/16/07, 08/21/08, 08/20/09, 08/19/10, 08/18/11, 8/16/12, 08/15/13, 08/21/14
POLICY NUMBER: 2.02.18 CATEGORY: Laboratory Tests	PAGE: 1 OF 5
<ul style="list-style-type: none">• <i>If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.</i>• <i>Medical policies apply to commercial and Medicaid products only when a contract benefit for the specific service exists.</i>• <i>Medical policies only apply to Medicare products when a contract benefit exists and where there are no National or Local Medicare coverage decisions for the specific service.</i>	

POLICY STATEMENT:

Based upon our criteria and the lack of peer-reviewed literature, serum and urinary markers of bone turnover have not been proven to improve patient outcomes and are **investigational** for, but not limited to, the following indications:

- I. *Monitoring treatment* for osteoporosis or other conditions associated with increased bone turnover; or
- II. *Identification or diagnosis* of osteoporosis or other conditions associated with increased bone turnover

Refer to Corporate Medical Policy # 6.01.05 regarding Bone Densitometry/Bone Density Studies.

Refer to Corporate Medical Policy # 11.01.03 regarding Experimental or Investigational Services.

POLICY GUIDELINES:

The Federal Employee Health Benefit Program (FEHBP/FEP) requires that procedures, devices or laboratory tests approved by the U.S. Food and Drug Administration (FDA) may not be considered investigational and thus these procedures, devices or laboratory tests may be assessed only on the basis of their medical necessity.

DESCRIPTION:

After cessation of growth, bone is in a constant state of remodeling (or turnover), with initial absorption of bone by osteoclasts followed by deposition of new bone matrix by osteoblasts. This constant bone turnover is critical to the overall health of the bone, by repairing microfractures and remodeling the bony architecture in response to stress to the skeletal structure. Normally, the action of osteoblasts and osteoclasts is balanced, but bone loss can occur if the two processes become uncoupled. It has been proposed that bone remodeling can be assessed by the measurement of surrogate markers of bone turnover in the blood or urine.

Biochemical markers of bone turnover can be categorized as either bone formation markers or bone resorption markers (see list below). Collagen cross links may be the best available markers of bone resorption. They bind 3 molecules of collagen in the bone and are released from the bone matrix after resorption. They may be detected using Pyr and dPyr or immunoassays (Pyr, D-Pyr, CTx, NTx).

I. Formation Markers

- A. Serum osteocalcin (OC),
- B. Serum total alkaline phosphatase (ALP),
- C. Serum bone specific alkaline phosphatase (BSAP),
- D. Serum procollagen I carboxyterminal propeptide (PICP),
- E. Serum procollagen type I N-terminal propeptide (PINP), and
- F. Bone sialoprotein.

II. Resorption Markers

- A. Serum and urinary hydroxyproline (Hyp),
- B. Urinary total pyridinoline (Pyr),
- C. Urinary total deoxypyridinoline (dPyr),
- D. Urinary free pyridinoline (f-Pyr or Pyrilinks®),
- E. Urinary free deoxypyridinoline (f-dPyr or Pyrilinks-D®),

Proprietary Information of Excellus Health Plan, Inc.

SUBJECT: BIOCHEMICAL MARKERS OF BONE TURNOVER POLICY NUMBER: 2.02.18 CATEGORY: Laboratory Tests	EFFECTIVE DATE: 02/20/03 REVISED DATE: 12/18/03, 12/16/04, 10/20/05, 08/17/06, 08/16/07, 08/21/08, 08/20/09, 08/19/10, 08/18/11, 08/16/12, 08/15/13, 08/21/14 PAGE: 2 OF:5
--	---

- F. Urinary or serum collagen type I cross-linked N-telopeptide A (NTx or Osteomark's NTx® test),
- G. Urinary or serum collagen type I cross-linked C-telopeptide (CTx or Cross Laps®),
- H. Serum carboxyterminal telopeptide or I collagen (ITCP), and
- I. Tartrate-resistant acid phosphatase (TRAP).

Biochemical markers of bone turnover have been researched in diseases associated with markedly high levels of bone turnover, such as Paget's disease, primary hyperparathyroidism, glucocorticoid-induced osteoporosis, or renal osteodystrophy. There is interest in the use of these markers to evaluate age-related osteoporosis. Currently fracture risk is based primarily on measurements of bone mineral density (BMD) in conjunction with other genetic and environmental factors, such as family history of osteoporosis, history of smoking, and weight.

It is thought that the level of biochemical markers of bone turnover may also predict fracture risk. However, the presence of these markers in serum or urine is not necessarily related to bone loss. Even if bone turnover is high, if resorption is balanced with formation, there will be no net bone loss. Bone loss will only occur if resorption exceeds formation. Therefore, these markers have been primarily studied as an adjunct, not an alternative, to measurements of bone mineral density, to estimate the fracture risk and document the need for preventive or therapeutic strategies for osteoporosis.

RATIONALE:

The following clinical applications of bone-turnover markers have been investigated:

- I. In conjunction with measurements of bone mineral densitometry, as a technique to identify those patients at highest risk of osteoporosis-related fractures. Bone-turnover markers may reflect fracture risk through a different mechanism than that associated with BMD. Therefore, markers had been investigated as an adjunct to BMD to increase the prediction assessment for fracture risk compared to the use of BMD alone. It is not clear at this time how therapy should be adjusted according to the level of fracture risk or whether the use of bone-turnover markers could predict response to therapy.
- II. To provide a more immediate assessment of treatment response and predict change in BMD in response to treatment. Treatment-related changes in BMD occur very slowly. This fact, coupled with the precision of BMD technologies, suggest that clinically significant changes in BMD can not be reliably detected until at least 2 years. In contrast, changes in bone-turnover markers could be anticipated after 3 months of therapy. Although bone-turnover markers might be assessed at diagnosis to provide a baseline, followed by repeat assay at 3 months to determine the response to therapy, studies report an inconsistent relationship between the change in bone-turnover markers in response to therapy and the magnitude of subsequent change in BMD. In addition, there is marked diurnal variation in bone-turnover markers in individual patients, and results of markers measured in the urine had to be correlated to the serum creatinine, all of which complicated the interpretation of serial studies.
- III. As an alternative to an additional central measurement. If a patient has been initially diagnosed with osteoporosis using a peripheral BMD measurement, some physicians may recommend an additional BMD of the more clinically relevant central sites, i.e., the hip and spine, to serve as a baseline for future serial measurements of BMD. This strategy thus requires two BMD measurements in patients with osteoporosis. In this setting, bone-turnover markers had been proposed as an alternative to an additional central measurement.
- IV. Use in other diseases associated with high bone-turnover rates, such as glucocorticoid-induced osteoporosis, hyperparathyroidism, or renal osteodystrophy. Similar to the discussion above regarding age-related osteoporosis, it is unclear how levels of collagen cross link as a marker of bone turnover might be used in the management of the patient.

Updated guidelines from the National Osteoporosis Foundation (2013) indicate biochemical marker changes in individuals must exceed the least significant change in order to be clinically meaningful. The least significant change is specific to the biomarker being utilized, which is calculated by multiplying the "precision error" of the specific biochemical marker (laboratory provided) by 2.77 (95% confidence level). Biological variability can be reduced by obtaining samples in the early morning after an overnight fast. Serial measurements should be made at the same time of day. In order to have any clinical validity, sequential testing needs to be performed at the same laboratory.

SUBJECT: BIOCHEMICAL MARKERS OF BONE TURNOVER POLICY NUMBER: 2.02.18 CATEGORY: Laboratory Tests	EFFECTIVE DATE: 02/20/03 REVISED DATE: 12/18/03, 12/16/04, 10/20/05, 08/17/06, 08/16/07, 08/21/08, 08/20/09, 08/19/10, 08/18/11, 08/16/12, 08/15/13, 08/21/14 PAGE: 3 OF:5
--	---

In 2010, the North American Menopause Society issued an updated position statement on management of osteoporosis in postmenopausal women. The statement included the recommendation, “the routine use of biochemical markers of bone turnover in clinical practice is not generally recommended.”

According to conclusions reached by the National Institutes of Health and the Agency for Healthcare Research and Quality, the sensitivity and specificity of bone turnover markers are too low to be useful in identifying patients for treatment of osteoporosis and no marker is accurate enough to reliably identify individuals who fail to respond to therapy. There are a number of variables that can influence the results of bone marker tests, drugs (corticosteroids, anticonvulsants, and certain types of diuretics), the circadian cycle, the need for separate reference ranges based on age, sex and menopause and type of test. It is because of these factors and limitations that biochemical markers of bone turnover are of limited utility in the diagnosis and management of individuals with osteoporosis or other conditions associated with increased bone turnover.

Current literature indicates that alternative measures of bone strength have the potential to assess individual responses to treatment or identify individuals at high risk of future fracture, thereby potentially altering clinical management. However, current methods for measuring markers of bone turnover are not sufficiently sensitive (the least significant change) to reliably determine individual treatment responses, and other types of assays appear to be at an early stage of development. Current methods of assessing bone turnover have not been shown to improve health outcomes.

CODES: Number Description

Eligibility for reimbursement is based upon the benefits set forth in the member’s subscriber contract.

CODES MAY NOT BE COVERED UNDER ALL CIRCUMSTANCES. PLEASE READ THE POLICY AND GUIDELINES STATEMENTS CAREFULLY.

Codes may not be all inclusive as the AMA and CMS code updates may occur more frequently than policy updates.

Code Key: Experimental/Investigational = (E/I), Not medically necessary/ appropriate = (NMN).

CPT: 82523 (E/I) Collagen cross links, any method
 83937 (E/I) Osteocalcin (bone gla protein)

Copyright © 2014 American Medical Association, Chicago, IL

HCPCS: No code(s)

ICD9: 733.00-733.09 Osteoporosis
 733.10-733.19 Pathologic Fractures

ICD10: Includes A codes only:
 M48.50xA-M48.58xA Collapsed vertebra (code range)
 M80.00xA-M81.8 Osteoporosis with current pathological fracture (code range)
 M84.40xA-M84.48xA Pathological fracture (code range)
 M84.50xA-M84.58xA Pathological fracture in neoplastic disease (code range)
 M84.60xA-M84.68xA Pathological fracture in other disease (code range)

REFERENCES:

*Agency for Healthcare Research and Quality. Evidence Report/Technology Assessment #28: Osteoporosis in postmenopausal women: diagnosis and monitoring. Publication #01-E032. 2001 Feb.

BlueCross BlueShield Association. Collagen cross links as markers of bone turnover. Medical Policy Reference Manual Policy #2.04.15. 2013 Oct 10.

SUBJECT: BIOCHEMICAL MARKERS OF BONE TURNOVER POLICY NUMBER: 2.02.18 CATEGORY: Laboratory Tests	EFFECTIVE DATE: 02/20/03 REVISED DATE: 12/18/03, 12/16/04, 10/20/05, 08/17/06, 08/16/07, 08/21/08, 08/20/09, 08/19/10, 08/18/11, 08/16/12, 08/15/13, 08/21/14 PAGE: 4 OF:5
--	---

BonAdASIA study group. Impact of bone marker feedback on adherence to once monthly ibandronate for osteoporosis among Asian postmenopausal women. Int J Rheum Dis 2009 Sep;12(3):216-24.

Brown JP, et al. Bone turnover markers in the management of postmenopausal osteoporosis. Clin Biochem 2009 Jul;42(10-11):929-42.

Chopin F, et al. Prognostic interest of bone turnover markers in the management of postmenopausal osteoporosis. Joint Bone Spine 2012 Jan;79(1):26-31.

Compston J. Monitoring osteoporosis treatment. Best Pract Res Clin Rheumatol 2009 Dec;23(6):781-8.

Eastell R, et al. Bone turnover markers: a key tool for understanding osteoporosis. Osteoporos Int 2009;20(Supp3):S237-8.

Farahmand P, et al. Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis. Osteoporos Int 2013 Dec;24(12):2971-81.

*Garnero P, et al. Long-term variability of markers of bone turnover in postmenopausal women and implications for their clinical use: the OFELY study. J Bone Miner Res 2003 Oct;18(10):1789-94.

Huang Q, et al. Biochemical-markers for the diagnosis of bone metastasis: A review of clinical. Cancer Epidemiol 2011 Apr 6 [Epub ahead of print].

Krege JH, et al. PINP as a biological response marker during teriparatide treatment for osteoporosis. Osteoporos Int 2014 Mar 6 [Epub ahead of print].

Lenora J, et al. Use of bone turnover markers in osteoporosis. Clinic Rev Bone Miner Metab 2009 [Epub Ahead of print].

McCloskey EV, et al. Official positions for FRAX clinical regarding biochemical markers from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX. J Clin Densitom 2011 Jul-Sep;14(3):220-2.

National Osteoporosis Foundation. Newly revised 2013 clinician's guide to prevention and treatment of osteoporosis. [http://www.nof.org/hcp/clinicians-guide] accessed 7/14/14.

North American Menopause Society. Management of osteoporosis in postmenopausal women: 2010 position statement. Menopause: The Journal of the North American Menopause Society. 2010;17(1):23-56.

*Prestwood KM, et al. Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial. JAMA 2003 Aug 27;290(8):1042-8.

Romero Barco CM, et al. Biochemical markers in osteoporosis: usefulness in clinical practice. Rheumatol Clin 2012 May-Jun;8(3):149-52.

Saad F, et al. Biochemical marker of bone turnover and clinical outcomes in men with prostate cancer. Urol Oncol 2012 July;30(4):369-378.

*Scariano JK, et al. Critical differences in the serial measurement of three biochemical markers of bone turnover in the sera of pre-and postmenopausal women. Clin Biochem 2001 Nov;34(8):639-44.

Sculz P. The role of bone turnover markers in monitoring treatment in postmenopausal osteoporosis. Clin Biochem 2012 Aug;45(12):907-19.

*Szulc P, et al. Biochemical markers of bone turnover in men. Calcif Tissue Internat 2001 Oct;69(4):229-34.

Terreni A, et al. Biochemical markers in the follow-up of the osteoporotic patients. Clin Cases Miner Bone Metab 2012 May;9(2):80-4.

SUBJECT: BIOCHEMICAL MARKERS OF BONE TURNOVER POLICY NUMBER: 2.02.18 CATEGORY: Laboratory Tests	EFFECTIVE DATE: 02/20/03 REVISED DATE: 12/18/03, 12/16/04, 10/20/05, 08/17/06, 08/16/07, 08/21/08, 08/20/09, 08/19/10, 08/18/11, 08/16/12, 08/15/13, 08/21/14 PAGE: 5 OF:5
--	---

*Valimaki MJ, et al. Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial. Clin Ther 2007 Sep;29(9):1937-49.

Van Spil WE, et al. Serum and urinary biochemical markers for knee and hip-osteoarthritis: a systematic review applying the consensus BIPED criteria. Osteoarthritis Cartilage 2010 May;18(5):605-12.

*Vergnaud P, et al. Is the predictive power of previous fractures for new spine and non-spine fractures associated with biochemical evidence of altered bone remodeling? The EPOS study. European prospective osteoporosis study. Clin Chim Acta 2002 Aug;322(1-2):121-32.

Wheater G, et al. The clinical utility of bone marker measurements in osteoporosis. J Transl Med 2013 Aug 29;11:201.

KEY WORDS:

Bone resorption, Collagen cross links, NTx, ITCP.

CMS COVERAGE FOR MEDICARE PRODUCT MEMBERS

There is currently a National Coverage Determination (NCD) for Collagen Crosslinks, any method. Please refer to the following NCD website for Medicare Members: <http://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=96&ncdver=1&bc=AgAAgAAAAAA&>.